Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Pagegroup profits slump in 'challenging' conditions

(Sharecast News) - Recruiter Pagegroup reported a slump in full-year profit on Thursday amid "challenging" market conditions. In the year to the end of December 2023, pre-tax profit fell 39.6% to £117.4m, while revenue nudged up 1% to £2.01bn. Operating profit slid 39.4% to £118.8m.

The recruiter cited "tougher trading conditions" during the year, particularly in permanent recruitment, whereas temporary was more resilient.

Chief executive Nicholas Kirk said: "We produced a resilient performance in 2023 in challenging market conditions. Despite the year-on-year decline in gross profit and operating profit, we saw good activity levels through most of the year, albeit the conversion of final interviews to accepted offers and therefore gross profit became increasingly challenging due to ongoing lower levels of candidate and client confidence.

"We saw a slower end to 2023 due to macro uncertainty impacting candidate and client sentiment, which has continued into January and February, albeit they are two of the smallest months of the year from a trading perspective."

At 0810 GMT, the shares were down 1.4% at 450.60p.

Share this article

Related Sharecast Articles

UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Somero trading in line with expectations
(Sharecast News) - Somero Enterprises said in an update on Monday that trading for the first five months of 2024 was consistent with expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.